Charles River - JP Morgan Conference Presentation
Best-in-class science and service
driving robust demand
DSA: Focused on preclinical R&D support
M&A and technology partnerships enhancing scale, innovative
capabilities and therapeutic area expertise
distributed bio
RETROGENIX™
SPOTTING YOUR TARGET.
WILRESEARCH
MPI
citoxlab
RESEARCH
Safety and Health Research
A CHARLES RIVER COMPANY
Robust demand driven by greater outsourcing by biopharma clients
-
- Opportunity to drive incremental outsourcing penetration with Discovery only
~25% outsourced and Safety Assessment 60%+ outsourced
•
Biotech leveraging outsourcing expertise to drive innovation, instead of building
in-house capabilities
Large biopharma utilizing scientific partners like CRL, in place of maintaining
internal resources
Significant opportunity to further increase synergies and client overlap
- More than half of Discovery clients remained with CRL for safety assessment
over last three years
Charles River - JP Morgan Conference Presentation
12View entire presentation